As graphed in Figure 1(c), HHLA2 mRNA levels also increased significantly in breast invasive carcinoma (BRCA), CHOL, COAD, esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), HNSC, KICH, KIRC, KIRP, acute myeloid leukemia (LAML), brain lower-grade glioma (LGG), lung adenocarcinoma (LUAD), LUSC, pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), READ, stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), uterine corpus endometrial carcinoma (UCEC), and uterine carcinosarcoma (UCS). This evidence concerns the gene HHLA2 and acute myeloid leukemia.